文献速递血栓与止血

血栓性血小板减少性紫癜

Thrombotic thrombocytopenic purpura.
PubMed 文献 · Blood · 2017-04-17

血栓性血小板减少性紫癜(TTP)是一种罕见且危及生命的血栓性微血管病,与ADAMTS13严重缺乏相关,多为获得性自身抗体所致。女性发病率约高2倍,具有复发倾向。急性期一线治疗为每日治疗性血浆置换,联合或不联合类固醇;难治性病例可考虑强化治疗。

要点

  • TTP表现为微血管病性溶血性贫血、重度血小板减少和器官缺血。
  • ADAMTS13严重缺乏是TTP的核心特征,多为获得性自身抗体所致。
  • 急性TTP一线治疗为每日治疗性血浆置换,联合或不联合类固醇。

核心结论

  • TTP是一种罕见且危及生命的血栓性微血管病,与ADAMTS13严重缺乏相关,具有复发倾向。
  • 快速识别TTP对于启动适当治疗至关重要。
  • TTP女性发病率约为男性的2倍。

研究设计与样本

  • 本文为综述,未报告系统检索范围。

主要发现

  • TTP的特征为微血管病性溶血性贫血、重度血小板减少和器官缺血,与弥漫性微血管富血小板血栓相关。
  • ADAMTS13缺乏最常见通过ADAMTS13自身抗体获得,罕见情况下通过ADAMTS13基因突变遗传。
  • 首次急性TTP发作通常发生在成年期,以抗ADAMTS13自身免疫病因为主;罕见情况下TTP始于儿童期,常为遗传性。
  • 难治性或无应答TTP可考虑更强化治疗,包括每日两次血浆置换、环磷酰胺/长春新碱/环孢素A脉冲或挽救性脾切除术。
  • 新药包括N-乙酰半胱氨酸、硼替佐米、重组ADAMTS13和caplacizumab在TTP管理中显示前景。

关键数值与推荐

  • 急性TTP一线治疗基于每日治疗性血浆置换补充缺乏的ADAMTS13,联合或不联合类固醇。
  • 针对ADAMTS13自身抗体的额外免疫调节主要基于类固醇和人源化抗CD20单克隆抗体利妥昔单抗。
  • 难治性或无应答TTP可考虑每日两次血浆置换、环磷酰胺脉冲、长春新碱脉冲、环孢素A脉冲或挽救性脾切除术。

临床怎么用

  • 快速识别TTP以启动适当治疗。
  • 长期随访TTP患者以识别其他自身免疫病、控制复发并评估心理生理后遗症。
  • 仍需全球患者登记和创新药物的进一步开发以改善TTP管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, severe thrombocytopenia, and organ ischemia linked to disseminated microvascular platelet rich-thrombi. TTP is specifically related to a severe deficiency in ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13), the specific von Willebrand factor-cleaving protease. ADAMTS13 deficiency is most frequently acquired via ADAMTS13 autoantibodies, but rarely, it is inherited via mutations of the ADAMTS13 gene. The first acute episode of TTP usually occurs during adulthood, with a predominant anti-ADAMTS13 autoimmune etiology. In rare cases, however, TTP begins as soon as childhood, with frequent inherited forms. TTP is ∼2-fold more frequent in women, and its outcome is characterized by a relapsing tendency. Rapid recognition of TTP is crucial to initiate appropriate treatment. The first-line therapy for acute TTP is based on daily therapeutic plasma exchange supplying deficient ADAMTS13, with or without steroids. Additional immune modulators targeting ADAMTS13 autoantibodies are mainly based on steroids and the humanized anti-CD20 monoclonal antibody rituximab. In refractory or unresponsive TTP, more intensive therapies including twice-daily plasma exchange; pulses of cyclophosphamide, vincristine, or cyclosporine A; or salvage splenectomy are considered. New drugs including N-acetylcysteine, bortezomib, recombinant ADAMTS13, and caplacizumab show promise in the management of TTP. Also, long-term follow-up of patients with TTP is crucial to identify the occurrence of other autoimmune diseases, to control relapses, and to evaluate psychophysical sequelae. Further development of both patients' registries worldwide and innovative drugs is still needed to improve TTP management.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Joly BS, Coppo P, Veyradier A, et al. Thrombotic thrombocytopenic purpura. Blood. 2017. PMID: 28416507. doi:10.1182/blood-2016-10-709857

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。